Innovation

Here you can learn how to add new statistical methods to your toolbox. These may not be neccessarily cutting edge methods, but approaches, that you are not yet aware about.

Driving Statistical Innovation – Barriers And Strategies Part 1

Statistical innovation is vital in the pharmaceutical industry as it drives evidence-based decisions and brings value to patients. However, it requires a delicate balance between invention and commercialization to achieve success. I, together with Mouna Akacha and Kaspar Rufibach – two leaders of statistical innovation groups in big pharma companies, share their insights on the …

Driving Statistical Innovation – Barriers And Strategies Part 1 Read More »

Framework for estimating policy estimands

In our world of clinical trials and observational studies, missing data based on drop outs or for others reasons leads to a challenge in understanding how well treatments work. Treatment policy estimands help us to understand efficacy based on early treatment decisions. Various approaches, like reference-based imputation and delta adjustment, exist to speculate what may have …

Framework for estimating policy estimands Read More »

Your compound through the eyes of the competition

In any industry, staying competitive and relevant requires a constant focus on innovation and the ability to communicate effectively with customers. In the pharmaceutical industry, this is particularly true as companies race to develop and market new compounds that can improve patient outcomes. In this episode, I share insights into the importance of effective data …

Your compound through the eyes of the competition Read More »

Beyond Regulatory and HTA Success: Reaching Physicians and Patients

We statisticians play a significant role in the clinical development of pharmaceutical products and medical devices. Many of us focus on designing and analyzing clinical trials to provide evidence for regulatory approval and Health Technology Assessment (HTA). In these set-up, we often talk rather directly to our external clients – regulators and payers (at least …

Beyond Regulatory and HTA Success: Reaching Physicians and Patients Read More »